Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGC NASDAQ:ENTA NASDAQ:KLRS NASDAQ:SOPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGCCanopy Growth$0.96-4.0%$1.04$0.84▼$2.38$430.48M0.7910.29 million shs5.74 million shsENTAEnanta Pharmaceuticals$14.51-4.0%$13.40$6.43▼$17.15$421.95M0.96201,682 shs204,960 shsKLRSKalaris Therapeutics$4.65-2.1%$4.80$2.14▼$11.88$110.63M0.1977,177 shs49,656 shsSOPHSOPHiA GENETICS$5.34-0.2%$5.11$2.81▼$6.30$448.84M0.96186,502 shs503,409 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGCCanopy Growth0.00%+7.07%-2.91%-1.96%-22.78%ENTAEnanta Pharmaceuticals0.00%+7.93%+33.95%+14.04%+91.51%KLRSKalaris Therapeutics0.00%+9.95%+6.98%-24.24%+90.00%SOPHSOPHiA GENETICS0.00%-6.96%+7.00%+8.08%+78.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGCCanopy Growth$0.96-4.0%$1.04$0.84▼$2.38$430.48M0.7910.29 million shs5.74 million shsENTAEnanta Pharmaceuticals$14.51-4.0%$13.40$6.43▼$17.15$421.95M0.96201,682 shs204,960 shsKLRSKalaris Therapeutics$4.65-2.1%$4.80$2.14▼$11.88$110.63M0.1977,177 shs49,656 shsSOPHSOPHiA GENETICS$5.34-0.2%$5.11$2.81▼$6.30$448.84M0.96186,502 shs503,409 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGCCanopy Growth0.00%+7.07%-2.91%-1.96%-22.78%ENTAEnanta Pharmaceuticals0.00%+7.93%+33.95%+14.04%+91.51%KLRSKalaris Therapeutics0.00%+9.95%+6.98%-24.24%+90.00%SOPHSOPHiA GENETICS0.00%-6.96%+7.00%+8.08%+78.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGCCanopy Growth 2.17HoldN/AN/AENTAEnanta Pharmaceuticals 2.75Moderate Buy$20.2939.81% UpsideKLRSKalaris Therapeutics 2.78Moderate Buy$15.60235.48% UpsideSOPHSOPHiA GENETICS 2.33Hold$7.5040.45% UpsideCurrent Analyst Ratings BreakdownLatest KLRS, SOPH, CGC, and ENTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026CGCCanopy Growth Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/23/2026KLRSKalaris Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/23/2026ENTAEnanta Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.006/15/2026CGCCanopy Growth Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/15/2026KLRSKalaris Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/15/2026SOPHSOPHiA GENETICS BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.006/9/2026KLRSKalaris Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/1/2026CGCCanopy Growth Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026CGCCanopy Growth Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026KLRSKalaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.005/14/2026KLRSKalaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.00(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGCCanopy Growth$284.60M1.51N/AN/A$1.13 per share0.85ENTAEnanta Pharmaceuticals$65.32M6.46N/AN/A$3.03 per share4.79KLRSKalaris TherapeuticsN/AN/AN/AN/A$4.21 per shareN/ASOPHSOPHiA GENETICS$77.27M5.80N/AN/A$0.69 per share7.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGCCanopy Growth-$190.29M-$0.59N/AN/AN/A-75.27%-26.95%-17.20%8/7/2026 (Estimated)ENTAEnanta Pharmaceuticals-$81.89M-$2.59N/AN/AN/A-89.56%-64.04%-20.22%8/10/2026 (Confirmed)KLRSKalaris Therapeutics-$43.44M-$2.15N/AN/AN/AN/A-72.78%-43.49%N/ASOPHSOPHiA GENETICS-$79M-$0.52N/AN/AN/A-44.48%-62.74%-21.85%8/4/2026 (Estimated)Latest KLRS, SOPH, CGC, and ENTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/15/2026Q4 2026CGCCanopy Growth-$0.06-$0.17-$0.11-$0.05$53.43 million$51.22 million5/12/2026Q1 2026KLRSKalaris Therapeutics-$0.52-$0.46+$0.06-$0.46N/AN/A5/11/2026Q2 2026ENTAEnanta Pharmaceuticals-$0.46-$0.45+$0.01-$0.45$17.03 million$17.16 million5/5/2026Q1 2026SOPHSOPHiA GENETICS-$0.2325-$0.27-$0.0375-$0.27$20.40 million$21.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGCCanopy GrowthN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AKLRSKalaris TherapeuticsN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGCCanopy Growth0.313.342.64ENTAEnanta PharmaceuticalsN/A3.843.84KLRSKalaris TherapeuticsN/A12.1912.19SOPHSOPHiA GENETICS1.052.061.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGCCanopy Growth3.33%ENTAEnanta Pharmaceuticals94.99%KLRSKalaris Therapeutics66.05%SOPHSOPHiA GENETICS31.59%Insider OwnershipCompanyInsider OwnershipCGCCanopy Growth0.16%ENTAEnanta Pharmaceuticals11.48%KLRSKalaris Therapeutics68.10%SOPHSOPHiA GENETICS4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGCCanopy Growth1,128448.42 million447.70 millionOptionableENTAEnanta Pharmaceuticals16029.08 million25.74 millionOptionableKLRSKalaris Therapeutics11023.79 million7.59 millionN/ASOPHSOPHiA GENETICS52083.89 million79.80 millionNot OptionableKLRS, SOPH, CGC, and ENTA HeadlinesRecent News About These CompaniesSOPHiA GENETICS (NASDAQ:SOPH) CEO Jurgi Camblong Sells 50,069 SharesJune 30, 2026 | insidertrades.comInsider Selling: SOPHiA GENETICS (NASDAQ:SOPH) CEO Sells $290,400.20 in StockJune 29, 2026 | marketbeat.comSOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $27,500.00 in StockJune 29, 2026 | americanbankingnews.comSOPHiA GENETICS (NASDAQ:SOPH) CTO Sells $38,261.44 in StockJune 29, 2026 | americanbankingnews.comSOPHiA GENETICS Calls 2026 AGM as It Highlights Breakout 2025 GrowthJune 29, 2026 | theglobeandmail.comSOPHiA GENETICS (NASDAQ:SOPH) Insider Philippe Menu Sells 5,000 SharesJune 27, 2026 | insidertrades.comSOPHiA GENETICS (NASDAQ:SOPH) Insider Philippe Menu Sells 5,000 Shares of StockJune 26, 2026 | marketbeat.comIs SOPHiA GENETICS SA (SOPH) Among the Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On?June 24, 2026 | finance.yahoo.comSOPHiA GENETICS Shareholders Back 2025 Results, Board Line-Up and Capital Changes at June 18 AGMJune 22, 2026 | tipranks.comSOPHiA GENETICS Publishes Results of the 2026 Annual General MeetingJune 22, 2026 | prnewswire.comSOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional SharesJune 19, 2026 | prnewswire.comSophia Genetics Shares Rise After $50M Stock Offering PricingJune 18, 2026 | marketwatch.comSOPHiA Genetics: Strong Growth Meets A Critical Execution PhaseJune 18, 2026 | seekingalpha.comSophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionJune 17, 2026 | benzinga.comSOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary SharesJune 16, 2026 | prnewswire.comSOPHiA GENETICS Announces Proposed Public Offering of Ordinary SharesJune 16, 2026 | prnewswire.comJurgi Camblong Sells 8,500 Shares of SOPHiA GENETICS (NASDAQ:SOPH) StockJune 11, 2026 | marketbeat.comSOPHiA GENETICS names Ross Muken CEO and co-founder Camblong as chairman nomineeJune 11, 2026 | msn.comSOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General MeetingJune 10, 2026 | prnewswire.comSophia Genetics, Memorial Sloan Kettering sign strategic collab for AI-powered precision oncology hubJune 9, 2026 | fiercehealthcare.comFInsider Spends US$99k Buying More Shares In SOPHiA GENETICSJune 7, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKLRS, SOPH, CGC, and ENTA Company DescriptionsCanopy Growth NASDAQ:CGC$0.96 -0.04 (-4.00%) Closing price 04:00 PM EasternExtended Trading$0.97 +0.01 (+0.63%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.Enanta Pharmaceuticals NASDAQ:ENTA$14.51 -0.60 (-3.97%) Closing price 04:00 PM EasternExtended Trading$14.52 +0.02 (+0.10%) As of 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Kalaris Therapeutics NASDAQ:KLRS$4.65 -0.10 (-2.11%) Closing price 04:00 PM EasternExtended Trading$4.68 +0.02 (+0.54%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.SOPHiA GENETICS NASDAQ:SOPH$5.34 -0.01 (-0.19%) Closing price 04:00 PM EasternExtended Trading$5.26 -0.08 (-1.40%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
